enVVeno Q1 FY26 net loss narrows 15% to $3.8 million

• enVVeno Medical posted a net loss of USD 3.8 million for three months ended March 31, 2026, narrowing 15% year over year.
• Research and development expense fell 17% to USD 2.1 million; selling, general and administrative expense dropped 19% to USD 2 million.
• Other income declined 53% to USD 0.2 million.
• Cash and investments totaled USD 24.9 million as of March 31, 2026; cash burn expected to rise to USD 4 million-USD 5 million per quarter in 2026, with funding projected into third-quarter 2027.
• FDA cleared the IDE for the TAVVE pivotal study of the transcatheter enVVe System; first stage targets 10 patients with 30-day safety data, followed by a 220-patient randomized stage across up to 40 U.S. sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enVVeno Medical Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021490), on May 06, 2026, and is solely responsible for the information contained therein.